Afatinib (BIBW2992)

Catalog No.S1011

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Cited by 74 Publications

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )
Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )
Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )
Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jtOmlEPTB;MD6wNFU4OiEQvF2=	MVjTRW5ITVJ?
KASUMI-1	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7HR5pKSzVyPUCuNFA6OTFizszN	NVO4e2ZoW0GQR1XS
HCC2218	M{i1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEC5PFch\|ryP	MnraV2FPT0WU
KARPAS-45	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7FTWM2OD1yLkCxOlcyKM7:TR?=	MnvmV2FPT0WU
HSC-4	NVL4UmFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHJcZdSUUN3ME2wMlAyPzR6IN88US=>	NEDvS2NUSU6JRWK=
CHL-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33UUGlEPTB;MD6wNVg{QSEQvF2=	M2L2[XNCVkeHUh?=
KY821	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\RTWM2OD1yLkCyNFYh\|ryP	MX;TRW5ITVJ?
NCI-N87	NYSwO3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPSeFNKSzVyPUCuNFI4PzNizszN	MWTTRW5ITVJ?
DOK	M2K2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fSdWlEPTB;MD6wN\|E6PCEQvF2=	M3LGSHNCVkeHUh?=
DSH1	NF7GWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrsTWM2OD1yLkCzN\|E1KM7:TR?=	Mm[1V2FPT0WU
MDA-MB-175-VII	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nnSGlEPTB;MD6wN\|QyPiEQvF2=	MWrTRW5ITVJ?
NCI-H2170	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV2yNZM3UUN3ME2wMlA{PzJ6IN88US=>	NWTLPI46W0GQR1XS
BT-474	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rTNGlEPTB;MD6wOFk5PiEQvF2=	MoXQV2FPT0WU
EFO-27	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrHTWM2OD1yLkC1NVgzKM7:TR?=	NIPsR\|ZUSU6JRWK=
NCI-H720	NXTsPWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPCR4FZUUN3ME2wMlA2OzJ3IN88US=>	NWTUOZFCW0GQR1XS
PC-14	M1PrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjGenJKSzVyPUCuNFU3PjhizszN	NIPrfHNUSU6JRWK=
EC-GI-10	NV22VopoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYK2emVNUUN3ME2wMlA2QTF{IN88US=>	MWTTRW5ITVJ?
KYSE-450	NHLNeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;yV\|lKSzVyPUCuNFU6PzhizszN	MYfTRW5ITVJ?
BPH-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G2VWlEPTB;MD6wOVk5QCEQvF2=	MlzEV2FPT0WU
NCI-H292	NVTRdYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4e5R2lEPTB;MD6wOlA6KM7:TR?=	M{fKcHNCVkeHUh?=
H9	NX3Le4JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLtVVFZUUN3ME2wMlA4OTN{IN88US=>	M{nNc3NCVkeHUh?=
NCI-H526	NIe5[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXqxUId1UUN3ME2wMlA4QDJ\|IN88US=>	MVXTRW5ITVJ?
NCI-H1623	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\OTWlEPTB;MD6wPFAzPSEQvF2=	MlnZV2FPT0WU
KYSE-140	M1Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEizN{DPxE1?	NGXZeGdUSU6JRWK=
Ca9-22	NVvuRpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnVR5dOUUN3ME2wMlA5OzV\|IN88US=>	NGXMR4JUSU6JRWK=
AU565	NEXIbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O2N2lEPTB;MD6wPFUxPCEQvF2=	NWmyTXFOW0GQR1XS
ZR-75-30	M1KwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{H5UGlEPTB;MD6wPVU1PSEQvF2=	MkHyV2FPT0WU
NCI-H1770	MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{OzfGlEPTB;MD6xNFI5KM7:TR?=	Ml;zV2FPT0WU
LB2241-RCC	M1HTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzOZ\|JKSzVyPUCuNVA5QDRizszN	MUPTRW5ITVJ?
CAL-39	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;OZnRpUUN3ME2wMlEyPzl{IN88US=>	NXvlfYJuW0GQR1XS
UACC-893	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILy[pRKSzVyPUCuNVE5QDVizszN	MlfKV2FPT0WU
LU-65	NG\1VoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkKxTWM2OD1yLkGyOlM{KM7:TR?=	NYnVb2hSW0GQR1XS
HN	NFzofXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDYeFNKSzVyPUCuNVMxPzdizszN	MnfuV2FPT0WU
TI-73	NY\I[\|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMUS3NVUh\|ryP	M3LlfnNCVkeHUh?=
KU812	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTOdmtKSzVyPUCuNVU1PTZizszN	M3nL[HNCVkeHUh?=
SW13	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX72cXQ4UUN3ME2wMlE3OjF4IN88US=>	M3jEeXNCVkeHUh?=
BB30-HNC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\w[3NKSzVyPUCuNVY2PzZizszN	NGnSS3dUSU6JRWK=
HSC-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXpUolLUUN3ME2wMlE3QDN5IN88US=>	M4LXXnNCVkeHUh?=
BV-173	NX61fW4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Gxb2lEPTB;MD6xO\|U6PiEQvF2=	NFjvSZFUSU6JRWK=
CAL-27	NHO1RXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULwN2FCUUN3ME2wMlE4PjN4IN88US=>	M2TRVXNCVkeHUh?=
SBC-1	NGrZfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnDcGZMUUN3ME2wMlE5QTV7IN88US=>	Ml\zV2FPT0WU
CAL-33	M3fYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:2emNKSzVyPUCuNlAyQDRizszN	M4j1d3NCVkeHUh?=
NCI-H209	M4n5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMkC0OkDPxE1?	M4GwNHNCVkeHUh?=
COR-L105	M2nucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnMWoNKSzVyPUCuNlExQDRizszN	MmD5V2FPT0WU
HSC-3	NXLTNHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMkGxPVgh\|ryP	M2PkT3NCVkeHUh?=
NCI-H69	NFO1N2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfBW4ZKSzVyPUCuNlE1PTFizszN	M1XE[HNCVkeHUh?=
MOLT-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGT2R2tKSzVyPUCuNlM6PzVizszN	MmSxV2FPT0WU
ML-2	NXnHNJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrF[3Z5UUN3ME2wMlI1QDB{IN88US=>	M1P5[XNCVkeHUh?=
IGROV-1	NIKzUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf0OVBKSzVyPUCuNlU6PTJizszN	MlnMV2FPT0WU
TK10	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnsNHpRUUN3ME2wMlI3PzN6IN88US=>	M3z6TnNCVkeHUh?=
EoL-1-cell	M4LTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvPVVJWUUN3ME2wMlI3QDl{IN88US=>	NHjkS5NUSU6JRWK=
HO-1-N-1	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFK2eWRKSzVyPUCuNlc5PTNizszN	MlXHV2FPT0WU
BHY	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PvZmlEPTB;MD6yPFY2PSEQvF2=	NYXC[JpWW0GQR1XS
LU-139	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHCTWM2OD1yLkOwOVEh\|ryP	NIXNZVJUSU6JRWK=
23132-87	NYSwVWwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXHTWM2OD1yLkOxPVI{KM7:TR?=	M{\Y[nNCVkeHUh?=
ACHN	M3PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDsW4RKSzVyPUCuN\|E6QTRizszN	MnP1V2FPT0WU
DoTc2-4510	M{Hm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzl[2JKSzVyPUCuN\|IzOTlizszN	NWPaZ4RFW0GQR1XS
BB65-RCC	NULRRnVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGP1bYhKSzVyPUCuN\|Q2QTNizszN	MmD0V2FPT0WU
HLE	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILIcJBKSzVyPUCuN\|UxPDZizszN	Mk\mV2FPT0WU
HCC1419	NIjYZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfTTWM2OD1yLkO2OFA5KM7:TR?=	NEPsRWpUSU6JRWK=
A388	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HuXWlEPTB;MD6zOlg2PyEQvF2=	MnjoV2FPT0WU
NUGC-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXv3OY1DUUN3ME2wMlM5Ozd\|IN88US=>	NVvsRnRwW0GQR1XS
KYSE-180	NVPJU3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DmNWlEPTB;MD6zPVA5QSEQvF2=	NEfmdXZUSU6JRWK=
TE-6	NGnzbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfEWYhpUUN3ME2wMlQxOjR4IN88US=>	NV7UTYJvW0GQR1XS
A498	M1jac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPQTnE{UUN3ME2wMlQxPjd2IN88US=>	NILGNIJUSU6JRWK=
NCI-H1648	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXm2Wnl4UUN3ME2wMlQ1OTh{IN88US=>	NGXhPZdUSU6JRWK=
DU-145	NGLBUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHkRZpKSzVyPUCuOFQ5OzNizszN	MoG2V2FPT0WU
CW-2	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmSxTWM2OD1yLkS2PVE1KM7:TR?=	M{\DcnNCVkeHUh?=
A431	NGXVbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwNEiyN\|Mh\|ryP	NUDhUGpNW0GQR1XS
SAS	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn5TWM2OD1yLkS4N\|k5KM7:TR?=	NEe2No1USU6JRWK=
NCI-H2126	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfTTWM2OD1yLkWxPVI3KM7:TR?=	M{PNU3NCVkeHUh?=
NCI-H358	NYHrdIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzZTWM2OD1yLkWzNlEh\|ryP	NV7lUGZjW0GQR1XS
FADU	NYO2VZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEntPHVKSzVyPUCuOVQ1ODRizszN	MY\TRW5ITVJ?
ACN	NILNOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rMVWlEPTB;MD61OVA6PCEQvF2=	M1z4VnNCVkeHUh?=
HCC70	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjQNW9[UUN3ME2wMlU4PjZzIN88US=>	MXfTRW5ITVJ?
NCI-H1838	M4TqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjMZ4dKSzVyPUCuOlAzQTlizszN	NUm5c3JLW0GQR1XS
CAL-54	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\WXWo6UUN3ME2wMlYyPjJzIN88US=>	Mn\iV2FPT0WU
NCI-H1975	NGTXVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{H3TmlEPTB;MD62NVczQCEQvF2=	NWXBR4pEW0GQR1XS
COR-L88	M3O2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojKTWM2OD1yLk[0NVE{KM7:TR?=	M3v5OnNCVkeHUh?=
CTV-1	NWDofFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojMTWM2OD1yLk[0N\|kzKM7:TR?=	Mlq2V2FPT0WU
EW-18	M1vj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\iRoFnUUN3ME2wMlY5Pjl6IN88US=>	MXzTRW5ITVJ?
HCC1806	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjGdmZKSzVyPUCuOlk3PjZizszN	MlvSV2FPT0WU
HuP-T4	NXTyNpNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwNkm3OkDPxE1?	MYrTRW5ITVJ?
MDA-MB-361	NEfhflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwN{K2OlIh\|ryP	M{XUSXNCVkeHUh?=
NCI-H1573	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7KT2REUUN3ME2wMlc{PjNizszN	MVjTRW5ITVJ?
KU-19-19	M4fGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjiZWVDUUN3ME2wMlc4PDZ2IN88US=>	M4\KXHNCVkeHUh?=
COLO-678	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zxSGlEPTB;MD64NFg{PCEQvF2=	NEXQV5lUSU6JRWK=
C-33-A	NXnXXFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnSfHZpUUN3ME2wMlgyOjl5IN88US=>	Ml\BV2FPT0WU
Calu-3	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjBdZpUUUN3ME2wMlgyPDN2IN88US=>	MYrTRW5ITVJ?
AGS	M1rFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlSxTWM2OD1yLkizOlQ5KM7:TR?=	M3;5UnNCVkeHUh?=
SCC-25	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEThfWpKSzVyPUCuPFQyPzFizszN	NWjhV2RrW0GQR1XS
JVM-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jhXmlEPTB;MD64PFI6QSEQvF2=	MluzV2FPT0WU
HCE-T	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoP4TWM2OD1yLki4OFI5KM7:TR?=	NYjEdJl5W0GQR1XS
ES4	MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwOUe4N\|Yh\|ryP	NYjIb4lRW0GQR1XS
EKVX	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfBZnc4UUN3ME2xMlAyODZ2IN88US=>	MU\TRW5ITVJ?
D-542MG	NILEeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrzTmtsUUN3ME2xMlAyODZ2IN88US=>	NUD4bJpHW0GQR1XS
SW1116	NWTkWpA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLJTWM2OD1zLkCxNlg4KM7:TR?=	MX;TRW5ITVJ?
5637	NWPKSXVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fTeGlEPTB;MT6wNVUyKM7:TR?=	M{jTWHNCVkeHUh?=
HT-1376	NF;MSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwMEG1NVMh\|ryP	MXLTRW5ITVJ?
NB69	NFjKcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DicmlEPTB;MT6wNlk1PSEQvF2=	MofHV2FPT0WU
YKG-1	NVHKNXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwMEW0NVkh\|ryP	Ml2zV2FPT0WU
EW-3	NHOzTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHhTWM2OD1zLkC3PFg{KM7:TR?=	NUDYb4htW0GQR1XS
GCIY	M4TUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr5VpNKSzVyPUGuNFgyODRizszN	MXrTRW5ITVJ?
SK-MES-1	MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG3Rm5WUUN3ME2xMlEyPDh5IN88US=>	MlWwV2FPT0WU
PANC-08-13	MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jTcmlEPTB;MT6xOlQyPiEQvF2=	MV7TRW5ITVJ?
SK-NEP-1	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFwMUe1NVMh\|ryP	MWXTRW5ITVJ?
SW954	M4LueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPXTWM2OD1zLkKwNlE1KM7:TR?=	MVPTRW5ITVJ?
NCI-SNU-5	NXrwb5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7U[GtKSzVyPUGuNlM6KM7:TR?=	NEPqWmdUSU6JRWK=
SW48	M3fsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnJNlllUUN3ME2xMlI2PDN{IN88US=>	M3j4TXNCVkeHUh?=
HT-3	NUT4bpE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHDTWM2OD1zLkK4O\|U{KM7:TR?=	MoXzV2FPT0WU
ETK-1	NHHoTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj2TWM2OD1zLkO3OFU3KM7:TR?=	MnWwV2FPT0WU
SCC-15	NHjafIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjYS3lzUUN3ME2xMlM6PDVzIN88US=>	NWD5UZZxW0GQR1XS
DU-4475	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzXTWM2OD1zLkSwNVIyKM7:TR?=	NGSxR25USU6JRWK=
NB5	NEO1bIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jIcmlEPTB;MT60NVMyPyEQvF2=	NHXMPHZUSU6JRWK=
CFPAC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVq2emNTUUN3ME2xMlQzPDl\|IN88US=>	M4HWbHNCVkeHUh?=
NCI-H630	M13xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj0TWM2OD1zLkS1OVgzKM7:TR?=	NHXr[G1USU6JRWK=
NCI-H82	NGTS[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zwXGlEPTB;MT61OFAxPiEQvF2=	NXXEOlk2W0GQR1XS
ECC10	NIn4W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jCU2lEPTB;MT61OVM3QSEQvF2=	Mlv5V2FPT0WU
K5	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTZTWM2OD1zLkW4N\|U4KM7:TR?=	MYfTRW5ITVJ?
ME-180	NXXPRpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwNkGwPVYh\|ryP	MYfTRW5ITVJ?
KYSE-410	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\jZZl1UUN3ME2xMlY2Pjd{IN88US=>	MXXTRW5ITVJ?
G-401	NUTqSG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIP4PYdKSzVyPUGuOlc1OTNizszN	NFPSRZBUSU6JRWK=
TGBC24TKB	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;aOFRKSzVyPUGuOlgzOyEQvF2=	M1\NPHNCVkeHUh?=
Detroit562	NVrQOVdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS4TWM2OD1zLkewNVUzKM7:TR?=	NIjSV5VUSU6JRWK=
OE19	MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fIPGlEPTB;MT63NVUyOiEQvF2=	MnzVV2FPT0WU
CAKI-1	NFzNSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTFwN{iyNVEh\|ryP	M4e5bnNCVkeHUh?=
TE-12	NHXDSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrqc4tKSzVyPUGuPFA1OTRizszN	NUXY[pRQW0GQR1XS
NCI-H1666	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXUTWM2OD1zLkiwPVQ5KM7:TR?=	NFjKXJhUSU6JRWK=
TE-1	NUn5VFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPRTWM2OD1zLkixOFc2KM7:TR?=	MoLuV2FPT0WU
CAL-12T	NGXOVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID1c\|JKSzVyPUGuPFg6PDVizszN	M3TBVXNCVkeHUh?=
TE-8	NH\CT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTaNXdsUUN3ME2xMlkyOzd5IN88US=>	MUfTRW5ITVJ?
KYSE-270	M{exXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTSUXRuUUN3ME2yMlAzPzN{IN88US=>	MVjTRW5ITVJ?
GMS-10	M2fKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnLTWM2OD1{LkCzOVE4KM7:TR?=	MY\TRW5ITVJ?
A2780	M4HnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWP4VVZXUUN3ME2yMlA3Ojl2IN88US=>	MmDXV2FPT0WU
OMC-1	NGrMWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjNR4NJUUN3ME2yMlA5OTZ7IN88US=>	NIDOOJFUSU6JRWK=
LoVo	M2LF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTJwMUC3PVch\|ryP	NW\TTYFKW0GQR1XS
PANC-03-27	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTJwMU[2N\|Eh\|ryP	NHvjZnRUSU6JRWK=
MDA-MB-157	NYPuNopVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nRc2lEPTB;Mj6yNVgzQCEQvF2=	MnLyV2FPT0WU
CaR-1	NVPOO5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjp[JVKSzVyPUKuNlgzQDFizszN	MWLTRW5ITVJ?
769-P	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfmNndKSzVyPUKuNlkxOzdizszN	MoHVV2FPT0WU
NB7	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHYU5hxUUN3ME2yMlI6Pjd4IN88US=>	Mmj6V2FPT0WU
MKN7	M2fOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHuTWM2OD1{LkO1N\|M2KM7:TR?=	MVLTRW5ITVJ?
NCI-H1048	M2fKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkn6TWM2OD1{LkS5NVU5KM7:TR?=	NGrK[mVUSU6JRWK=
RCM-1	NIXDfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1j4PWlEPTB;Mj61Nlk{QCEQvF2=	NEjucHRUSU6JRWK=
HT55	NUPmSXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLyTWM2OD1{LkW3N\|gh\|ryP	NV;QZ4hVW0GQR1XS
HCC1569	M37rZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLLcJlKSzVyPUKuOVgzQTdizszN	NWLOPJlyW0GQR1XS
LXF-289	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTJwNkO1OlUh\|ryP	NULqUGRLW0GQR1XS
OVCAR-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrTNYc3UUN3ME2yMlY4OTZ5IN88US=>	M4nLR3NCVkeHUh?=
TE-10	NVPIdYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvLTWM2OD1{Lk[4NFc5KM7:TR?=	MkjCV2FPT0WU
SNU-C2B	NFfNSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfITWM2OD1{Lk[4OlE3KM7:TR?=	NVPke2hPW0GQR1XS
LB1047-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3r6SGlEPTB;Mj63OFg5QCEQvF2=	NEC0[Y1USU6JRWK=
SN12C	NF3Lc\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlm1TWM2OD1{LkmxPVY1KM7:TR?=	M1S2SHNCVkeHUh?=
786-0	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorETWM2OD1\|LkC2OFA5KM7:TR?=	MXnTRW5ITVJ?
HT-29	M2TnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDkZYRoUUN3ME2zMlA4OzB7IN88US=>	NXrsO45JW0GQR1XS
RPMI-7951	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTNwMEe1PUDPxE1?	MnLDV2FPT0WU
NBsusSR	MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTNwMUiyOVQh\|ryP	MmXMV2FPT0WU
NKM-1	NXHncnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmm2TWM2OD1\|LkG4O\|Q1KM7:TR?=	NULtbnZJW0GQR1XS
Capan-2	M33uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXL[29KSzVyPUOuOFY5PzVizszN	MYLTRW5ITVJ?
MKN1	M3L0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTNwNEexNFgh\|ryP	MXnTRW5ITVJ?
OAW-42	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjZUpEzUUN3ME2zMlUxODJ4IN88US=>	NYm3VlJEW0GQR1XS
SKG-IIIa	NFHCTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXtTWM2OD1\|LkWyNlM4KM7:TR?=	MXnTRW5ITVJ?
no-11	M3PQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKzSZZKSzVyPUOuOVM2PjRizszN	NHjTZYFUSU6JRWK=
NY	NVWwRWFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jUNWlEPTB;Mz61N\|Y2PSEQvF2=	NFPCTZZUSU6JRWK=
HEC-1	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTNwNUi5OUDPxE1?	MVnTRW5ITVJ?
NCI-H441	M2fjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7KOGJ{UUN3ME2zMlU6QDRzIN88US=>	MXnTRW5ITVJ?
NCI-H2009	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH2TWM2OD1\|Lk[xNlE3KM7:TR?=	NEfXXWxUSU6JRWK=
T47D	M1S3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\MTWM2OD1\|Lk[yNlE4KM7:TR?=	NXHGR4d1W0GQR1XS
SNU-449	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTNwNkW4NlYh\|ryP	MV\TRW5ITVJ?
NCI-SNU-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\uR2JKSzVyPUOuOlk4OzVizszN	MXzTRW5ITVJ?
BT-20	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3zVGVKSzVyPUOuOlk4QTVizszN	MYHTRW5ITVJ?
LS-123	NUjjWFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTHbHZZUUN3ME2zMlc1Ojh2IN88US=>	M3m1R3NCVkeHUh?=
8305C	MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLidJFvUUN3ME2zMlc2QTFzIN88US=>	M13yW3NCVkeHUh?=
OCUB-M	M1SwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrtb2xKSzVyPUOuO\|YyQDdizszN	NVm4VmlYW0GQR1XS
KOSC-2	NELSdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNwOEO0OVEh\|ryP	MUTTRW5ITVJ?
NCI-H1693	NG\RcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTNwOESxPFEh\|ryP	NGrVTVdUSU6JRWK=
TE-9	M{\rZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTNwOESzPFIh\|ryP	MkHRV2FPT0WU
MV-4-11	NV:xRnIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vCemlEPTB;Mz64O\|k6PCEQvF2=	M1\QTnNCVkeHUh?=
GAMG	NUixXmw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTNwOUGzNVQh\|ryP	MkfvV2FPT0WU
KNS-62	NYXvcmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofzTWM2OD1\|Lkm0O\|MyKM7:TR?=	MoD1V2FPT0WU
MC116	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX6TWM2OD1\|Lkm1OFg6KM7:TR?=	NEL1eXBUSU6JRWK=
647-V	NVrFUGJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrMTWM2OD1\|Lkm4OFUzKM7:TR?=	MWjTRW5ITVJ?
U-87-MG	NU\UUG1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLCTWM2OD12LkGwOFgyKM7:TR?=	MVjTRW5ITVJ?
RPMI-8226	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHpclNKSzVyPUSuNVE3OzFizszN	MXHTRW5ITVJ?
SW1417	NHzYUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDyWYxKSzVyPUSuNVIyPDdizszN	MX3TRW5ITVJ?
LAMA-84	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXBTWM2OD12LkG3NFIh\|ryP	M2CyVHNCVkeHUh?=
LS-513	NYDnUZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYO5Z3VIUUN3ME20MlMyOjF5IN88US=>	MkHvV2FPT0WU
KLE	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjpSm1wUUN3ME20MlQxQDF7IN88US=>	NFzIdnBUSU6JRWK=
HCT-116	NGXJOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfmWIhGUUN3ME20MlQyODB5IN88US=>	MVLTRW5ITVJ?
EPLC-272H	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\HTWM2OD12LkSxOVM{KM7:TR?=	NHnXcoRUSU6JRWK=
KS-1	NYDV[4RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX0epdlUUN3ME20MlUxQDh7IN88US=>	M{XTZXNCVkeHUh?=
HT-1197	NEPRe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv5codKSzVyPUSuOVI3PjlizszN	MoXwV2FPT0WU
LCLC-97TM1	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTRwNUO2PFYh\|ryP	M1jYbHNCVkeHUh?=
ES5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTRwOEO3NlMh\|ryP	MUXTRW5ITVJ?
CTB-1	NX3DbJY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrNZpBKSzVyPUSuPFQ5QCEQvF2=	NGPVO2xUSU6JRWK=
HL-60	NXPIO\|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXizT\|dmUUN3ME20Mlg3PjFzIN88US=>	MW\TRW5ITVJ?
VM-CUB-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfKTWM2OD12Lki2PFE6KM7:TR?=	M3rqbnNCVkeHUh?=
MEG-01	M{GxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTRwOUm0NFMh\|ryP	NIC3WWhUSU6JRWK=
KYSE-520	NHLENGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PTPWlEPTB;NT6yNFg{QSEQvF2=	NFP5eIhUSU6JRWK=
HuO-3N1	M1m4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H6WGlEPTB;NT6yOFA1OyEQvF2=	NHz4b5hUSU6JRWK=
SW620	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjHS2xKSzVyPUWuNlQ6PjRizszN	NVvyPHVTW0GQR1XS
U031	NEXEeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmC1TWM2OD13LkK1OFI1KM7:TR?=	MlruV2FPT0WU
TE-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTVwNEC4OUDPxE1?	M2HIe3NCVkeHUh?=
NCI-H747	NFPvSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\n[VdKSzVyPUWuOFI1PzJizszN	Ml:wV2FPT0WU
MG-63	M4\lO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTVwNEi3OlIh\|ryP	Mk\WV2FPT0WU
HC-1	NF3RfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrxbFR2UUN3ME21MlUyQDN7IN88US=>	MnWzV2FPT0WU
HCC2998	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi2SnNGUUN3ME21MlUzPjF3IN88US=>	NInJbpJUSU6JRWK=
NTERA-S-cl-D1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknYTWM2OD13LkW0OVM4KM7:TR?=	M2ezenNCVkeHUh?=
KINGS-1	NFzHeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3Z[2oyUUN3ME21MlYxQTR2IN88US=>	MW\TRW5ITVJ?
D-423MG	M4HkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P3WmlEPTB;NT62NVcxPSEQvF2=	NXmzTWVMW0GQR1XS
SW962	NFfKbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fZU2lEPTB;NT62NlA{OiEQvF2=	MoLXV2FPT0WU
LOXIMVI	NYqxd4wxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTUTWM2OD13Lk[zPFc{KM7:TR?=	MU\TRW5ITVJ?
LS-411N	NEKxfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTVwN{m0OFEh\|ryP	MUfTRW5ITVJ?
NCI-H2291	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTVwOUi5OFMh\|ryP	M3LnOHNCVkeHUh?=
A549	NX;KNm5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HzcWlEPTB;Nj6xNlU2OyEQvF2=	NGnyUFFUSU6JRWK=
LS-1034	NXv2[WtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXHcJZKSzVyPU[uNlA4ODZizszN	M3LUU3NCVkeHUh?=
NB14	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTZwNEO4N\|Yh\|ryP	NXixTpdNW0GQR1XS
NCI-H1299	M135d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M133R2lEPTB;Nj62N\|E4OSEQvF2=	NFvvOoZUSU6JRWK=
BT-549	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jmOWlEPTB;Nj62Olg5QSEQvF2=	M{DQc3NCVkeHUh?=
J-RT3-T3-5	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzqcop5UUN3ME22Mlg3QSEQvF2=	NGjWWHpUSU6JRWK=
SW756	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjTXIlKSzVyPU[uPVEyPzZizszN	M4TuUHNCVkeHUh?=
DJM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHnW4R4UUN3ME22MlkzODF{IN88US=>	NH71WXVUSU6JRWK=
GP5d	Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrpTWM2OD14Lkm3N\|k1KM7:TR?=	MWLTRW5ITVJ?
MOLT-4	NHTZXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1K1V2lEPTB;Nz6wNlE{PSEQvF2=	MWHTRW5ITVJ?
NCI-H28	NXf6cWZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTdwMU[0NFUh\|ryP	NFXUcYhUSU6JRWK=
MN-60	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYW0T4NrUUN3ME23MlI5ODh7IN88US=>	NUjUSFRbW0GQR1XS
RMG-I	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\iTWM2OD15LkO5Nlk3KM7:TR?=	NGfNNHBUSU6JRWK=
COLO-800	NIfF[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTdwNEG0OFYh\|ryP	Mn7kV2FPT0WU
DB	M4nlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTdwNkGwNFUh\|ryP	Mkm0V2FPT0WU
Ca-Ski	NUXYfHVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPRTWM2OD15Lk[0NlU6KM7:TR?=	MmG1V2FPT0WU
HEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoriTWM2OD15LkexNlA{KM7:TR?=	MkGzV2FPT0WU
NH-12	M4jxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTdwN{K4NFgh\|ryP	MWTTRW5ITVJ?
LB373-MEL-D	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojxTWM2OD15Lke2O\|cyKM7:TR?=	MoXiV2FPT0WU
SW900	NHvpdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHPTWM2OD15LkiyNVIyKM7:TR?=	NWT4blRxW0GQR1XS
JVM-3	NGjsfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTdwOEm1PVkh\|ryP	NHXDZZRUSU6JRWK=
OAW-28	M1HBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFq2O3BKSzVyPUeuPVQ2PzhizszN	MVjTRW5ITVJ?
KURAMOCHI	M3H2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorXTWM2OD15Lkm0PFEyKM7:TR?=	M3;3RnNCVkeHUh?=
BE-13	NWnYNplLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT4fGtbUUN3ME23Mlk5OTF{IN88US=>	NU\kTnpDW0GQR1XS
VMRC-RCZ	NV7ZfXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj5S4cxUUN3ME24MlAyPjl5IN88US=>	M3jVNXNCVkeHUh?=
NCI-H727	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[yW2dnUUN3ME24MlExPDJizszN	NXPwR2RwW0GQR1XS
SW1710	M2HuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PDUmlEPTB;OD6xPFUyPSEQvF2=	MnvwV2FPT0WU
D-502MG	M2X5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRThwMkmyPFIh\|ryP	MWTTRW5ITVJ?
NCI-H1993	NYjsS5V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{S4[2lEPTB;OD6zN\|Y{OSEQvF2=	NVfhU21iW0GQR1XS
SCC-4	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnjS2RYUUN3ME24MlQ1ODV7IN88US=>	NIXBPXVUSU6JRWK=
HAL-01	NYPtPWZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYK3dppvUUN3ME24MlUyQTFizszN	NILpUFNUSU6JRWK=
GT3TKB	NYLTOFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTnSJRKSzVyPUiuOlc6PjRizszN	NF\5fHdUSU6JRWK=
SK-OV-3	NFLmdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3xNllKSzVyPUiuO\|E{OjlizszN	NGX2R2lUSU6JRWK=
COLO-829	MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX4TWM2OD16LkiwPVc3KM7:TR?=	MV;TRW5ITVJ?
OCI-AML2	NVTJRphKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7PTWM2OD16Lkm1OFgyKM7:TR?=	M4PFcHNCVkeHUh?=
OS-RC-2	M3XDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jsTmlEPTB;OT6wNlE6KM7:TR?=	MYXTRW5ITVJ?
BFTC-909	M1m4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXCTWM2OD17LkC2O\|k6KM7:TR?=	NWLQVZVlW0GQR1XS
EW-11	M{DrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XtNGlEPTB;OT6xO\|Y2OyEQvF2=	M{myVnNCVkeHUh?=
HCE-4	M{PtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fmc2lEPTB;OT6yNVU2QCEQvF2=	M1ewS3NCVkeHUh?=
BALL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTlwMkG5NFch\|ryP	MlXEV2FPT0WU
SF539	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\lTWM2OD17LkKzOVYzKM7:TR?=	M3P4VHNCVkeHUh?=
CAMA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4CxTWlEPTB;OT6yPFEzQCEQvF2=	NWfubJp{W0GQR1XS
C32	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTlwM{OwOlQh\|ryP	M4\RbHNCVkeHUh?=
NCI-H1703	NVTuV5dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3m[mNsUUN3ME25MlM1Ozd3IN88US=>	M2nsRnNCVkeHUh?=
NCI-H1650	NVvoO3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTlwNkC5OFYh\|ryP	NXzTeGdkW0GQR1XS
NCI-H1563	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXMTWM2OD17Lke2NFMyKM7:TR?=	MkXGV2FPT0WU
CAL-85-1	M3O3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTO[XpKSzVyPUmuPFc{QDNizszN	NYXVfmluW0GQR1XS
UM-UC-3	NF3RepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPjXG9YUUN3ME25Mlk2ODNizszN	NU\BbXJ[W0GQR1XS
BxPC-3	NH\zW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFyLkC5O\|Ih\|ryP	NHyycpVUSU6JRWK=
MHH-PREB-1	NYKxb5ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PtSGlEPTB;MUCuNVk6QSEQvF2=	M3PWfHNCVkeHUh?=
DEL	M3TtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPLTWM2OD1zMD6zPVQ3KM7:TR?=	NVrnV4RIW0GQR1XS
HuCCT1	NH\iNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zSU2lEPTB;MUCuOlA{OyEQvF2=	MYnTRW5ITVJ?
OVCAR-4	NVS2e\|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWSxWlRwUUN3ME2xNE45QDN3IN88US=>	MnzhV2FPT0WU
CAL-72	NF;MR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LrbGlEPTB;MUCuPVM6OSEQvF2=	MWLTRW5ITVJ?
HCC1954	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrxdYhiUUN3ME2xNU4xPzV2IN88US=>	M2HRcXNCVkeHUh?=
EFO-21	NIexOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi4SmFbUUN3ME2xNU4yODR3IN88US=>	MU\TRW5ITVJ?
FTC-133	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHwc3poUUN3ME2xNU4yPDB5IN88US=>	NIi2d2hUSU6JRWK=
SK-MEL-24	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXB[4k4UUN3ME2xNU4zOzZ4IN88US=>	NH\lVW9USU6JRWK=
UACC-62	NX:5Z5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jpSWlEPTB;MUGuNlM3QCEQvF2=	NWLCZW8{W0GQR1XS
NCI-H650	NHnVOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1e4[WlEPTB;MUGuNlQyQCEQvF2=	NXq0SJBzW0GQR1XS
ALL-PO	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe2ZWhKSzVyPUGxMlI2OTJizszN	MlfDV2FPT0WU
T84	M2TVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nrVGlEPTB;MUGuN\|kxPyEQvF2=	MkG2V2FPT0WU
IST-MEL1	NV;aW48zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfETWM2OD1zMT60OVU6KM7:TR?=	Mn;NV2FPT0WU
SW626	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7kTG9KSzVyPUGxMlU4PTVizszN	M4LoTXNCVkeHUh?=
RPMI-2650	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zFWGlEPTB;MUGuOVg5PSEQvF2=	MlvmV2FPT0WU
MC-IXC	NF3odVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnL1TWM2OD1zMT62O\|I5KM7:TR?=	M{nmdnNCVkeHUh?=
HOP-62	NXyyZ2UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\qTWM2OD1zMT62O\|Y1KM7:TR?=	MXrTRW5ITVJ?
NOS-1	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\6Z2lEPTB;MUGuO\|ExQSEQvF2=	NYDSclRwW0GQR1XS
SW1573	NUDwe3p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFzLkeyPVUh\|ryP	NUjYWXh2W0GQR1XS
WM-115	NWW3W2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVn3ZYN2UUN3ME2xNU44PTh6IN88US=>	Mon0V2FPT0WU
HuO9	MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7FTWM2OD1zMT64O\|c1KM7:TR?=	NEjKOW9USU6JRWK=
YAPC	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoX6TWM2OD1zMT65NlU6KM7:TR?=	NXnYW5V4W0GQR1XS
MDA-MB-453	M{HWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDkTWM2OD1zMT65OVE2KM7:TR?=	NH\QZ\|RUSU6JRWK=
NCI-H596	M1;JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEWxc5RKSzVyPUGyMlA{PjlizszN	MWfTRW5ITVJ?
A172	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTF{LkC3PVgh\|ryP	MnrmV2FPT0WU
RS4-11	NVHydFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjlTWM2OD1zMj6xO\|I2KM7:TR?=	MlixV2FPT0WU
HCC1937	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHPc45KSzVyPUGyMlc2PjRizszN	NVvKUnF3W0GQR1XS
SW837	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrkTWM2OD1zMj65NFI5KM7:TR?=	NXHpRmh5W0GQR1XS
NMC-G1	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D0fWlEPTB;MUKuPVI{PCEQvF2=	MkfGV2FPT0WU
PFSK-1	NVLHd5JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\LTWM2OD1zMz6wOkDPxE1?	MX;TRW5ITVJ?
DBTRG-05MG	NUT5bVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHPTJgzUUN3ME2xN{4xPjN{IN88US=>	M4\2NXNCVkeHUh?=
SK-UT-1	NUnabpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHWTWM2OD1zMz6xNFg{KM7:TR?=	NYHEVmdIW0GQR1XS
OVCAR-5	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV23OJZ7UUN3ME2xN{4yPTl\|IN88US=>	Mny0V2FPT0WU
8505C	NWLxe\|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnaTWM2OD1zMz6yNFY4KM7:TR?=	MljjV2FPT0WU
SK-MEL-1	M17Dd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;aWVRKSzVyPUGzMlcyOzVizszN	MWfTRW5ITVJ?
LK-2	M4[5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nzR2lEPTB;MUOuO\|Y{QSEQvF2=	Mne1V2FPT0WU
OE33	NGqzXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzlWlI2UUN3ME2xN{44QDZizszN	Mlv6V2FPT0WU
Ramos-2G6-4C10	NETPWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHTSYY{UUN3ME2xOE4xOjB{IN88US=>	NYXrc\|V5W0GQR1XS
EW-13	NVLZT2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDiOIdrUUN3ME2xOE4xOzV{IN88US=>	Mn\rV2FPT0WU
NCI-H1793	NWPnbJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj4VWdKSzVyPUG0MlIxQDdizszN	NXXhXpdFW0GQR1XS
BHT-101	NH3UOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF2LkK0NUDPxE1?	M2fNUnNCVkeHUh?=
RKO	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonlTWM2OD1zND61NFc2KM7:TR?=	MkW2V2FPT0WU
NEC8	M4X2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\oTWM2OD1zND61OFczKM7:TR?=	M13YR3NCVkeHUh?=
PANC-10-05	NWLIcXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;zSFFUUUN3ME2xOE43OjR5IN88US=>	NXf6U4pzW0GQR1XS
NCI-H2030	NWPVRWZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3oNHZoUUN3ME2xOE43PDR6IN88US=>	NGXzcYZUSU6JRWK=
C2BBe1	M3y3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTF2Lke2OEDPxE1?	M17EOXNCVkeHUh?=
EM-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzP[o5KSzVyPUG0Mlg2PzZizszN	MXTTRW5ITVJ?
HCC1395	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGW1NY1KSzVyPUG0Mlk{OzhizszN	MYHTRW5ITVJ?
A2058	NITGd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWGwd2o3UUN3ME2xOU4xPDB7IN88US=>	M2C1ZnNCVkeHUh?=
SW1463	M{\VNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{ixZmlEPTB;MUWuNFQ5PSEQvF2=	NH;hOVhUSU6JRWK=
J82	NWLFcZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHFTZNsUUN3ME2xOU4xPTdizszN	NYXKNIRnW0GQR1XS
CAL-120	NHXDc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTF3LkG0OFch\|ryP	NIrmUJRUSU6JRWK=
COLO-824	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHzTYtKSzVyPUG1MlE2PzlizszN	MWjTRW5ITVJ?
LNCaP-Clone-FGC	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Bc4VFUUN3ME2xOU41OjR6IN88US=>	MmfMV2FPT0WU
CP66-MEL	NILBVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HXUGlEPTB;MUWuOFY5QCEQvF2=	NXq4fVlRW0GQR1XS
OC-314	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVq5fXpbUUN3ME2xOU41PzF2IN88US=>	M4r5enNCVkeHUh?=
OVCAR-8	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\IW4tKSzVyPUG1Mlg5PjFizszN	MVrTRW5ITVJ?
MFE-280	NG\XbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjYTWM2OD1zNj6wOFg5KM7:TR?=	M2H6NXNCVkeHUh?=
MHH-NB-11	M{jDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfCVoVKSzVyPUG2MlA5OzlizszN	NEixe5ZUSU6JRWK=
SW1990	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfCTWM2OD1zNj6xO\|U2KM7:TR?=	M4HjZXNCVkeHUh?=
U-266	NYPnVmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHEW5VjUUN3ME2xOk4zOjl7IN88US=>	NULYVoFTW0GQR1XS
MFM-223	NXTHTnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLZTWM2OD1zNj6zPVY2KM7:TR?=	MWHTRW5ITVJ?
L-363	NGjJNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjJPHNKSzVyPUG2MlQ2PzdizszN	M33t[3NCVkeHUh?=
MCF7	NXnHflFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\ybow5UUN3ME2xOk41PzJ\|IN88US=>	MULTRW5ITVJ?
SK-MEL-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XMb2lEPTB;MU[uOFc5PyEQvF2=	NEPn[4dUSU6JRWK=
HH	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXhRWV1UUN3ME2xOk42OTZ{IN88US=>	NH6zR3VUSU6JRWK=
no-10	M1HhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LSOGlEPTB;MU[uOlM1OyEQvF2=	MYPTRW5ITVJ?
HuP-T3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIG4VZFKSzVyPUG2MlY2PzZizszN	MYHTRW5ITVJ?
QIMR-WIL	NYnLVGlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fEVGlEPTB;MU[uO\|ExPSEQvF2=	NVzjW3NUW0GQR1XS
NCI-H1092	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXE[Y9PUUN3ME2xOk45OzF4IN88US=>	MoPLV2FPT0WU
MZ2-MEL	M4O2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fRdGlEPTB;MU[uPFQxOyEQvF2=	MofIV2FPT0WU
ES3	M1j0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LHO2lEPTB;MU[uPVE{PCEQvF2=	MX7TRW5ITVJ?
COLO-684	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTF4Lkm0O\|ch\|ryP	NUXRUmdYW0GQR1XS
NCI-H661	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjMVoRKSzVyPUG2Mlk3QTRizszN	NGPFfppUSU6JRWK=
CP50-MEL-B	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTjV3ZRUUN3ME2xO{4xOzR\|IN88US=>	M1z6TXNCVkeHUh?=
NCI-H2405	MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrnTXVKSzVyPUG3MlE6PzRizszN	M{DNZXNCVkeHUh?=
U-2-OS	NUDmVY53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LyTmlEPTB;MUeuOVMxPyEQvF2=	MljEV2FPT0WU
RERF-LC-MS	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\RTWM2OD1zNz61OVA5KM7:TR?=	MoPVV2FPT0WU
NCI-H2342	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUniZ\|NFUUN3ME2xO{42PTdizszN	NEOxdVRUSU6JRWK=
ES8	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknETWM2OD1zNz62NFg4KM7:TR?=	MmjvV2FPT0WU
MOLT-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTsTWM2OD1zNz64PVM1KM7:TR?=	NIHwXVNUSU6JRWK=
RH-18	NHjrblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzYSHVIUUN3ME2xPE4xODN3IN88US=>	MmTPV2FPT0WU
D-283MED	NEPGWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTF6LkCwPFgh\|ryP	MkHkV2FPT0WU
RCC10RGB	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK0[nRKSzVyPUG4MlA2PTlizszN	MVzTRW5ITVJ?
NCI-H1437	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTZTWM2OD1zOD6xOlQyKM7:TR?=	MnLUV2FPT0WU
SW982	NVLocGw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrtd5NOUUN3ME2xPE4zPjdzIN88US=>	M{HVTnNCVkeHUh?=
IST-MES1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjMOXpyUUN3ME2xPE41PDJ6IN88US=>	MmO2V2FPT0WU
A704	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTF6LkS3OVMh\|ryP	NGDU[YZUSU6JRWK=
ESS-1	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\pd5FrUUN3ME2xPE42OjB3IN88US=>	NIj3ToNUSU6JRWK=
SCH	M4XqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPP[opKSzVyPUG4MlY1PTZizszN	NFvv[pJUSU6JRWK=
COLO-320-HSR	NFjudYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfub5A5UUN3ME2xPE44PDZizszN	MmXIV2FPT0WU
Mo-T	NWm5Z25bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTjdWJJUUN3ME2xPE45OjB2IN88US=>	MYrTRW5ITVJ?
Saos-2	NYPhcVdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIWwOoZKSzVyPUG5MlEyPjJizszN	NGHR[nZUSU6JRWK=
SW684	NGTib2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjuTWM2OD1zOT6xN\|I3KM7:TR?=	NX;GdGpHW0GQR1XS
KMOE-2	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nwSWlEPTB;MUmuNlI1OiEQvF2=	NEH0[XVUSU6JRWK=
MMAC-SF	NHTMe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF7LkK2NFch\|ryP	M{nCUHNCVkeHUh?=
JAR	NXqwTFR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHBTWM2OD1zOT6yPVkh\|ryP	Mo\XV2FPT0WU
SK-MEL-28	NHezWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn2TXlWUUN3ME2xPU4{OzZ\|IN88US=>	M4nNfnNCVkeHUh?=
KNS-81-FD	NHPlU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTF7LkW0Olgh\|ryP	MYLTRW5ITVJ?
ES7	M1XBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3qfnVoUUN3ME2xPU43Ojl{IN88US=>	NWD0SHBPW0GQR1XS
AsPC-1	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHm[VFKSzVyPUG5MlY1PzFizszN	NXraTVNYW0GQR1XS
NCI-H1155	NFLJeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF7LkeyN\|gh\|ryP	NUnPWVc2W0GQR1XS
KYSE-510	M2jMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PK[WlEPTB;MUmuPFc1QCEQvF2=	M2nEeHNCVkeHUh?=
ES1	M{jlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTF7LkmyNVMh\|ryP	MVXTRW5ITVJ?
PC-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTF7Lkm2NFQh\|ryP	MVXTRW5ITVJ?
GCT	M2fVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvySVlKSzVyPUKwMlMxOjZizszN	MUTTRW5ITVJ?
KARPAS-299	M{DTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvSUnY3UUN3ME2yNE4{PDJ{IN88US=>	NGjzWJVUSU6JRWK=
DOHH-2	NYrkTVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj5OVhKSzVyPUKwMlU1PjNizszN	M{PSWHNCVkeHUh?=
COLO-741	NEfBdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTJyLk[2JO69VQ>?	NE\FOZdUSU6JRWK=
NCI-H1395	NYDXZ5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjLO2pKSzVyPUKwMlY3QTdizszN	NUPhSFNxW0GQR1XS
HCC1187	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:5c2lEPTB;MkCuOlc{PCEQvF2=	MYPTRW5ITVJ?
Becker	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHruZ\|FKSzVyPUKwMlczODFizszN	MV;TRW5ITVJ?
LU-134-A	NFPWOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rzUmlEPTB;MkGuNVAzPiEQvF2=	NIjiS\|BUSU6JRWK=
MKN45	M374eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTOUVRmUUN3ME2yNU4yPTVzIN88US=>	NVvh[mRmW0GQR1XS
LC-2-ad	NUnqepMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vYVmlEPTB;MkGuNlczQSEQvF2=	MYXTRW5ITVJ?
EW-24	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGK2ZXJKSzVyPUKxMlM6PDVizszN	M4\kSXNCVkeHUh?=
SK-N-AS	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTJzLkiyO\|Yh\|ryP	Mlz2V2FPT0WU
NCI-H2052	NUnHOHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTJzLki5OlMh\|ryP	M175NnNCVkeHUh?=
A4-Fuk	NGHac4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLVTWM2OD1{Mj6xOFE6KM7:TR?=	NH\WNJNUSU6JRWK=
NB10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTJ{LkKzO\|Eh\|ryP	MmjmV2FPT0WU
CHP-212	M1nBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLSTWM2OD1{Mj6zNlIzKM7:TR?=	MkfSV2FPT0WU
KM12	M13zR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH0TJRKSzVyPUKyMlM2PiEQvF2=	NYflSlk2W0GQR1XS
JEG-3	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;UemlEPTB;MkKuN\|c5KM7:TR?=	M1nIWXNCVkeHUh?=
LN-405	NFTXbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1m4eGlEPTB;MkKuOVkyOyEQvF2=	NIrwNXdUSU6JRWK=
HCT-15	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nsfmlEPTB;MkKuO\|Q1OSEQvF2=	NILIPG5USU6JRWK=
MLMA	NVjvZ\|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHRPG1KSzVyPUKyMlc1PyEQvF2=	NGDWPXRUSU6JRWK=
GI-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTJ{Lke2OVgh\|ryP	MkHnV2FPT0WU
RT-112	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TUXGlEPTB;MkKuPFYyPiEQvF2=	MnzWV2FPT0WU
MPP-89	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTJ{Lki2OlEh\|ryP	NFnGV2ZUSU6JRWK=
A3-KAW	NFuzb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHHdIVKSzVyPUKzMlExODNizszN	M37H[nNCVkeHUh?=
KALS-1	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJ\|LkG0NVQh\|ryP	NGrJOlJUSU6JRWK=
SF126	MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4ntSGlEPTB;MkOuOlkzPCEQvF2=	NE\DRXpUSU6JRWK=
SiHa	M2DhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzLZ\|BKSzVyPUKzMlk{OjdizszN	MmP5V2FPT0WU
MDA-MB-415	NH\3NnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHU[WFKSzVyPUKzMlk1QTlizszN	NHfTd5FUSU6JRWK=
Daoy	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;KXmlEPTB;MkSuNVI3KM7:TR?=	MWPTRW5ITVJ?
COR-L23	NWXLNVZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjMRVNqUUN3ME2yOE4yPzZ5IN88US=>	MmLSV2FPT0WU
KG-1	M1jCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXLU3FKSzVyPUK0MlE6OjhizszN	NGnjSmRUSU6JRWK=
L-428	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXDfIFKSzVyPUK0MlU4QTFizszN	NGPaSYFUSU6JRWK=
NCI-H520	NImzTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTJ2Lki4OlEh\|ryP	NXzwZ5p[W0GQR1XS
COLO-792	M1rOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHOfohKSzVyPUK1MlI4OzJizszN	NHL3UnhUSU6JRWK=
NB12	NXHhPIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX21bFhTUUN3ME2yOU4zQTR5IN88US=>	MYPTRW5ITVJ?
GAK	NGXXTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLNTWM2OD1{NT6yPVY{KM7:TR?=	MVLTRW5ITVJ?
SW780	M2\1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPZZoJKSzVyPUK1MlMzPjRizszN	M1zoTXNCVkeHUh?=
GB-1	NFrmenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrMPZZKSzVyPUK1MlQxPjlizszN	MkPOV2FPT0WU
P12-ICHIKAWA	NXHoZYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrscotyUUN3ME2yOU41Pzh3IN88US=>	M3zzbHNCVkeHUh?=
NCI-H1651	NXqyU\|U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\XXIhKSzVyPUK1MlU6PyEQvF2=	MYrTRW5ITVJ?
KE-37	NVPsb3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTmTWM2OD1{NT63N\|E2KM7:TR?=	M2HUNXNCVkeHUh?=
CCRF-CEM	NIDpc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTJ3Lkm2O{DPxE1?	Mn;ZV2FPT0WU
SF295	NUPkT3lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Lsb2lEPTB;Mk[uNFQzPSEQvF2=	NELUVphUSU6JRWK=
G-361	NHfYU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mny4TWM2OD1{Nj6xNFI4KM7:TR?=	Mn7EV2FPT0WU
HOP-92	M3vXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP6PZVKSzVyPUK2MlEzOjZizszN	NVzaZXJQW0GQR1XS
UMC-11	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnaZ2xKSzVyPUK2MlQ2OTRizszN	MYDTRW5ITVJ?
IST-SL1	M1fqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTJ4Lk[1PVEh\|ryP	MUDTRW5ITVJ?
TE-11	NFnifW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHOTo03UUN3ME2yOk44PzV{IN88US=>	NUfsd20yW0GQR1XS
NCI-H1304	NWPJeI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTFdZlZUUN3ME2yOk46OTB6IN88US=>	MXTTRW5ITVJ?
SJSA-1	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\Rb4VWUUN3ME2yO{4xOTd4IN88US=>	M2rpbXNCVkeHUh?=
BCPAP	NELaNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJ5LkGzO{DPxE1?	NF7TSHBUSU6JRWK=
HTC-C3	NFjObnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnS5TWM2OD1{Nz6yOVYyKM7:TR?=	NEHO[4FUSU6JRWK=
EW-16	M{\sN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJ5LkK5OFch\|ryP	NIfXNJlUSU6JRWK=
HT-144	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXIcYRYUUN3ME2yO{41ODN{IN88US=>	NVr1[Zd5W0GQR1XS
MHH-ES-1	NEHKRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTJ5LkS0OFch\|ryP	MnzvV2FPT0WU
T98G	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TSfGlEPTB;MkeuOVg1PiEQvF2=	M3HScXNCVkeHUh?=
RPMI-8866	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDnO41bUUN3ME2yO{44PTZ{IN88US=>	NV[1U293W0GQR1XS
BEN	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTJSVVbUUN3ME2yO{45PTF5IN88US=>	NIT1b5NUSU6JRWK=
MDA-MB-231	NH3OS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTJ6LkK3PVUh\|ryP	MlTyV2FPT0WU
HuH-7	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmf6TWM2OD1{OD60NFI5KM7:TR?=	NIfXU3hUSU6JRWK=
SK-N-FI	NXrvTlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D3NWlEPTB;MkiuOFM{KM7:TR?=	MUDTRW5ITVJ?
AN3-CA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGiwcpNKSzVyPUK4MlQ{QTVizszN	NXLCcW9UW0GQR1XS
EGI-1	NUTJNndYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHpTWM2OD1{OD61PVI5KM7:TR?=	MYjTRW5ITVJ?
697	M{PBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULVV4ZUUUN3ME2yPE43OzNzIN88US=>	M3qwZXNCVkeHUh?=
TCCSUP	NV7HUFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{W2WmlEPTB;MkiuOlQyQCEQvF2=	MXjTRW5ITVJ?
GR-ST	NEDpdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zQTmlEPTB;MkiuOlY6PiEQvF2=	NX2xemZTW0GQR1XS
SK-N-DZ	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTkTWM2OD1{OD62PFg2KM7:TR?=	NV6xfYRjW0GQR1XS
MIA-PaCa-2	NHHpRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HqVmlEPTB;MkiuO\|k2QSEQvF2=	NVLTToJ1W0GQR1XS
IGR-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHLTWM2OD1{OD64PFc1KM7:TR?=	NGGxUZdUSU6JRWK=
BFTC-905	NWrpUJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTBUmRKSzVyPUK5MlI4ODVizszN	Mn3RV2FPT0WU
NCI-H1581	NX;HXGtmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTJ7LkOxOFUh\|ryP	Mn7kV2FPT0WU
RD	NHnNUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2T2WmlEPTB;MkmuOVI{OyEQvF2=	M1ryXHNCVkeHUh?=
SF268	M2DROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETsSItKSzVyPUK5MlU6OzFizszN	M1frO3NCVkeHUh?=
SHP-77	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPRTWM2OD1{OT62NVgzKM7:TR?=	NF;BSZZUSU6JRWK=
D-566MG	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPOTWM2OD1{OT65N\|k{KM7:TR?=	NEmxWVlUSU6JRWK=
TGBC1TKB	NEnUVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTNyLkGyN\|gh\|ryP	NYjsbJVlW0GQR1XS
MEL-HO	NEn1OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvpOIZHUUN3ME2zNE4yPDJ\|IN88US=>	M1jXc3NCVkeHUh?=
SJRH30	NX\6bWdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXeyb2tWUUN3ME2zNE4zOTB6IN88US=>	NI\v[JJUSU6JRWK=
D-336MG	MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7BOI1SUUN3ME2zNE4zQDl{IN88US=>	M{fBTXNCVkeHUh?=
C3A	NX22PHVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPObmxrUUN3ME2zNE4zQTJ5IN88US=>	NEj2XHJUSU6JRWK=
Calu-6	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7rZo5mUUN3ME2zNE4zQTZ\|IN88US=>	Mme1V2FPT0WU
MZ1-PC	NUDMbJB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnOTWM2OD1\|MD6zPVMh\|ryP	M1rZSXNCVkeHUh?=
KYSE-70	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3tTFV5UUN3ME2zNE42OTF2IN88US=>	MmHSV2FPT0WU
CAPAN-1	NYr0eI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTNyLkWxPFEh\|ryP	M3PSW3NCVkeHUh?=
DK-MG	NXjLSpp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTNyLkW0OVYh\|ryP	MnLQV2FPT0WU
SK-HEP-1	NEjRR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XC[GlEPTB;M{CuOlMzPiEQvF2=	M3vIUnNCVkeHUh?=
MS-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzYeZFKSzVyPUOwMlg5QDlizszN	M3PteHNCVkeHUh?=
GI-ME-N	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPjcnJKSzVyPUOxMlA2PzFizszN	MXrTRW5ITVJ?
NCI-H510A	NFKyO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTNzLkSwNFYh\|ryP	MlK2V2FPT0WU
NB17	NVW3XVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTNzLkWxPFUh\|ryP	M4Gyd3NCVkeHUh?=
639-V	NITDVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTNzLkWyOFMh\|ryP	NIm3VYlUSU6JRWK=
CAL-51	NIDKfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTNzLkW2Olch\|ryP	M2rCVHNCVkeHUh?=
HGC-27	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fMN2lEPTB;M{GuOVg4OyEQvF2=	MWXTRW5ITVJ?
GOTO	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTNzLki1NFYh\|ryP	NEHKfVFUSU6JRWK=
ChaGo-K-1	NXXsflVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTYTWM2OD1\|Mj6wNFch\|ryP	NEnLfWJUSU6JRWK=
RO82-W-1	NW\le4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7Md4NKSzVyPUOyMlE3ODRizszN	NV;vfXNZW0GQR1XS
SH-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPETWM2OD1\|Mj6xPFU5KM7:TR?=	NGO5c2xUSU6JRWK=
A204	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTN{LkWwOlkh\|ryP	M4j1[HNCVkeHUh?=
DMS-273	M3P6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHm2UZpKSzVyPUOyMlU{OjJizszN	MULTRW5ITVJ?
KGN	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXpTWM2OD1\|Mj62N\|Mh\|ryP	NEHtXIdUSU6JRWK=
SK-MEL-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\KTWM2OD1\|Mj62OVI4KM7:TR?=	MWPTRW5ITVJ?
NCI-H2228	NI\RN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO4TWM2OD1\|Mj62OlAzKM7:TR?=	NX7LOVc2W0GQR1XS
MKN28	NFS4XZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnGcWFJUUN3ME2zNk44QDN6IN88US=>	NEPJc\|FUSU6JRWK=
H-EMC-SS	NFfiVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXXTWM2OD1\|Mj65Olc5KM7:TR?=	NHzMSXdUSU6JRWK=
ATN-1	MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvw[lRJUUN3ME2zN{4yPDF4IN88US=>	NUPOdW5sW0GQR1XS
D-263MG	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfaTWM2OD1\|Mz64N\|c5KM7:TR?=	MoC0V2FPT0WU
LU-135	NIDiWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTtT\|VKSzVyPUOzMlg5OjlizszN	MU\TRW5ITVJ?
C8166	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTN\|Lki4OVQh\|ryP	M4HoenNCVkeHUh?=
T-24	NYHnTVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVqzb3dEUUN3ME2zOE4xOjB3IN88US=>	NHfnUXBUSU6JRWK=
Mewo	M1vC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTN2LkGzOFkh\|ryP	MVXTRW5ITVJ?
22RV1	MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTN2LkG3OVQh\|ryP	NYrIcYNHW0GQR1XS
KM-H2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFG1eXlKSzVyPUO0MlE4PzlizszN	NH;SdHRUSU6JRWK=
NCI-H2122	M1XXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTN2LkO0O\|Eh\|ryP	NFPufoFUSU6JRWK=
ABC-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHwTWM2OD1\|ND6zOlk{KM7:TR?=	NFjZSWRUSU6JRWK=
NCI-H1355	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDDPGdbUUN3ME2zOE4{QDh7IN88US=>	Ml\QV2FPT0WU
NOMO-1	M3LqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu3TWM2OD1\|ND61O\|A{KM7:TR?=	Mn\nV2FPT0WU
MZ7-mel	NX:2Z2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTN2Lk[0PFch\|ryP	M2rJTXNCVkeHUh?=
NCI-H810	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTN2LkeyO\|gh\|ryP	M2npZnNCVkeHUh?=
D-392MG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUi0VJVPUUN3ME2zOU4xPTZ3IN88US=>	NWPQOVVyW0GQR1XS
LB771-HNC	NGnDbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLmV\|hKSzVyPUO1MlE3PThizszN	MWLTRW5ITVJ?
COLO-679	NHjGPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfRPFVyUUN3ME2zOU4{QDhizszN	M3\iT3NCVkeHUh?=
SK-PN-DW	MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK0eVNIUUN3ME2zOU41OzZ7IN88US=>	MmPFV2FPT0WU
VA-ES-BJ	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHLTWM2OD1\|NT60OlQ6KM7:TR?=	NVu0XGRSW0GQR1XS
KNS-42	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoniTWM2OD1\|NT61PFI3KM7:TR?=	NXPUfWNuW0GQR1XS
RVH-421	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm4TWM2OD1\|NT63OlQ2KM7:TR?=	NEWzSGJUSU6JRWK=
P30-OHK	NILueGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TuXmlEPTB;M{WuPFc2OiEQvF2=	MofqV2FPT0WU
G-402	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;SWmlEPTB;M{WuPVg3PyEQvF2=	NVj5NI84W0GQR1XS
S-117	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3ibmNKSzVyPUO2MlMxODhizszN	NITTcoZUSU6JRWK=
RXF393	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGG5cJpKSzVyPUO2MlM4QDVizszN	NIrobJFUSU6JRWK=
LCLC-103H	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPadZZKSzVyPUO2Mlc5ODNizszN	NX7afmJ1W0GQR1XS
U-118-MG	M{PTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nZUGlEPTB;M{[uPFg1PyEQvF2=	M1OzUnNCVkeHUh?=
8-MG-BA	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTN4Lkm0PFMh\|ryP	NIXEcYtUSU6JRWK=
MFH-ino	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTN5LkOzO\|Eh\|ryP	NUTtWWlKW0GQR1XS
NCI-H23	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTN5LkSxPVYh\|ryP	MmP1V2FPT0WU
NCI-H446	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnriTWM2OD1\|Nz60PFYzKM7:TR?=	M2XlfHNCVkeHUh?=
LU-99A	NUH3PGl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTN5LkW3N\|Eh\|ryP	M1zsdHNCVkeHUh?=
KP-N-YN	NWHZfnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vkRmlEPTB;M{euOlE6PSEQvF2=	M1LKWHNCVkeHUh?=
SCC-9	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTN5Lke4N\|gh\|ryP	Mlv3V2FPT0WU
EFM-19	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTN5Lke5Olch\|ryP	NX\Udll1W0GQR1XS
A427	M2Ttbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTN5LkmxNFch\|ryP	M13UVXNCVkeHUh?=
LB831-BLC	NHzadYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlW4TWM2OD1\|OD62NFM6KM7:TR?=	MYXTRW5ITVJ?
HOS	NYPIems3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrnbllKSzVyPUO5MlYzPzNizszN	MmLzV2FPT0WU
LAN-6	NIrHWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PoZmlEPTB;NECuNFEyOiEQvF2=	MVnTRW5ITVJ?
U251	NI\Xe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW2TGY6UUN3ME20NE41ODV2IN88US=>	MX\TRW5ITVJ?
SNU-387	NIXN[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTRyLkS1OVMh\|ryP	M2C0R3NCVkeHUh?=
DMS-79	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P5O2lEPTB;NECuOVg5QSEQvF2=	MYXTRW5ITVJ?
SK-LU-1	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHMTWM2OD12MD62OVY5KM7:TR?=	M{Dlb3NCVkeHUh?=
HT	NUntc4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGwOpk4UUN3ME20NE43PjN7IN88US=>	M3XiPHNCVkeHUh?=
KP-N-YS	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfSTWM2OD12MD62O\|Y5KM7:TR?=	NIPFO3ZUSU6JRWK=
DMS-114	M2DuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTRyLkizO\|Qh\|ryP	MnLaV2FPT0WU
HUTU-80	NHv5O\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzLTWM2OD12MT6wOVY6KM7:TR?=	NHzGOIRUSU6JRWK=
ONS-76	NFW1U5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTRzLkS3NFkh\|ryP	M2n3ZnNCVkeHUh?=
A673	M{jsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTRzLkWxOVch\|ryP	MU\TRW5ITVJ?
HPAF-II	NFLadGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HrbmlEPTB;NEGuOlcxQSEQvF2=	NFntPFFUSU6JRWK=
UACC-257	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTRzLkezOlkh\|ryP	NHS3OVdUSU6JRWK=
EW-22	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoT0TWM2OD12MT64Olk4KM7:TR?=	NGL3NIxUSU6JRWK=
NCI-H1755	M4XNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTRzLki3NlUh\|ryP	NFnGNXZUSU6JRWK=
KYSE-150	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTR{LkG3PFIh\|ryP	MWnTRW5ITVJ?
CGTH-W-1	M4nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm0dodKSzVyPUSyMlQ6PTVizszN	M4PPNnNCVkeHUh?=
NB13	NXzHR\|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm5VnNKSzVyPUSyMlYzOTdizszN	MU\TRW5ITVJ?
SW872	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3tb45jUUN3ME20Nk43OzNzIN88US=>	Ml:1V2FPT0WU
KP-4	M{jlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTR{Lki4N\|Ih\|ryP	M3:4ZnNCVkeHUh?=
HCC38	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjqenJKSzVyPUSyMlk3OThizszN	NHS2[IFUSU6JRWK=
BB49-HNC	NILZWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTR\|LkKzOVYh\|ryP	MVTTRW5ITVJ?
CAL-62	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;yOFl4UUN3ME20N{41ODJ6IN88US=>	M4PEd3NCVkeHUh?=
NCI-H2029	NXPDfJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHOxWXVKSzVyPUSzMlU2QDFizszN	NVTF[3ViW0GQR1XS
M14	NHm0b4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTR2LkGzN\|Ih\|ryP	NEPqTFZUSU6JRWK=
COLO-680N	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3GTWM2OD12ND6zN\|kh\|ryP	MWnTRW5ITVJ?
Hs-578-T	NFz0eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnq[4pKSzVyPUS1MlAzQTRizszN	M2TUOHNCVkeHUh?=
MSTO-211H	MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTR3Lkm0PFIh\|ryP	NXzIfWx[W0GQR1XS
EW-1	NYnLXZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIG0XW9KSzVyPUS1Mlk3QDlizszN	M3m4Z3NCVkeHUh?=
SW948	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV70b4hZUUN3ME20Ok41PDZ{IN88US=>	MX7TRW5ITVJ?
NCI-H460	NFK3e\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\aUpBKSzVyPUS2MlUzOyEQvF2=	MlnTV2FPT0WU
CAS-1	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXHdHVKSzVyPUS2Mlc4ODFizszN	NXLEUXhPW0GQR1XS
TGBC11TKB	NV;OV3RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Ho[WlEPTB;NEeuNVc4PyEQvF2=	NIjiPXNUSU6JRWK=
HD-MY-Z	M{i3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Ph[mlEPTB;NEiuO\|g3KM7:TR?=	M4ewOHNCVkeHUh?=
NCI-H226	M2\nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlj4TWM2OD12OT63O\|g2KM7:TR?=	Mnu0V2FPT0WU
PA-1	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrac4NKSzVyPUS5Mlg{OzVizszN	NWS2SYl{W0GQR1XS
LB2518-MEL	NF33WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPPUHRKSzVyPUS5Mlg4OjNizszN	NHm4UY9USU6JRWK=
A101D	NFLVVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XFfmlEPTB;NEmuPVQzPSEQvF2=	M4jpT3NCVkeHUh?=
NCI-H2087	M1PGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1:wZ2lEPTB;NEmuPVY5OiEQvF2=	MYTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells.	25537503 26052929
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	+ Expand Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Athymic NMRI-nu/nu female mice Formulation: In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03827070	Recruiting	Non Small Cell Lung Cancer	Center Trials & Treatment Europe\|Center Trials & Treatment	March 5 2019	Phase 1
NCT03827070	Recruiting	Non Small Cell Lung Cancer	Center Trials & Treatment Europe\|Center Trials & Treatment	March 5 2019	Phase 1
NCT03727724	Active not recruiting	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Boehringer Ingelheim\|Merck Serono International SA	December 4 2018	Phase 2
NCT03727724	Active not recruiting	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Boehringer Ingelheim\|Merck Serono International SA	December 4 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products4

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 74 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 74 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)